血府逐瘀方治疗原发性痛经的随机安慰剂对照试验方案
本研究为多中心、随机、双盲、安慰剂对照试验方案,计划在6个中心招募248例原发性痛经患者,随机分为血府逐瘀方组与安慰剂组,每日服药三次,持续3个月经周期,随访12周。主要结局为VAS疼痛强度平均变化,次要结局包括疼痛持续时间、峰值疼痛强度、CMSS量表、EQ-5D-5L生活质量、止痛药累积用量及卫生经济学指标,同时报告不良事件。
要点
- 血府逐瘀方治疗原发性痛经尚缺乏高质量证据,本试验旨在填补该空白。
- 主要结局为VAS疼痛强度平均变化,随访12周。
- 次要结局涵盖疼痛持续时间、CMSS、EQ-5D-5L及止痛药用量。
核心结论
- 该方案拟通过多中心随机安慰剂对照试验评估血府逐瘀方治疗原发性痛经的疗效与安全性。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验方案,计划在6个中心招募248例原发性痛经患者。
- 参与者随机分为血府逐瘀方组与安慰剂组,每日服药三次,持续3个月经周期,随访12周。
关键数值与推荐
- 主要结局为VAS测量的疼痛强度平均变化。
- 次要结局包括月经疼痛持续时间变化、VAS峰值疼痛强度变化、CMSS、EQ-5D-5L、止痛药累积用量及卫生经济学指标。
- 不良事件也将被报告。
临床怎么用
- 该方案采用经验证的评估工具评价痛经严重程度,为血府逐瘀方治疗痛经提供证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epidemiological studies have shown that young women often suffer from primary dysmenorrhea (PD) which is a common cause that affects their routine work and quality of life. Chinese herbal medicine has been widely used for PD in China. A systematic review found that Xuefu Zhuyu (XFZY) has a promising effect on PD management, yet there is a dearth of high-quality evidence in support of this claim. We want to conduct a randomized controlled trial to evaluate the efficacy and safety of XFZY for PD patients. METHODS: This is a protocol for a multicenter, randomized, placebo-controlled trial. A total of 248 participants with PD will be recruited at 6 centers and randomized into two groups-a herbal treatment group and a placebo group. The participants will receive either XFZY or placebo, three times per day, for 3 menstrual cycles, with a 12-week follow-up. The primary outcome will be the mean change in pain intensity as measured by VAS, while the change in menstrual pain duration, the change in peak pain intensity as measured by VAS, the Cox Menstrual Symptom Scale (CMSS), quality of life EQ-5D-5L, cumulative painkiller consumption, and health economics will be included as secondary outcomes. Adverse events will also be reported. DISCUSSION: This protocol describes a multicenter, double-blind, randomized, placebo-controlled trial that investigates the efficacy and safety of XFZY for primary dysmenorrhea. Validated evaluation tools will assess dysmenorrhea severity. We believe that this research will provide important evidence regarding the use of XFZY to treat dysmenorrhea. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900026819 . Registered on 23 October 2019.
引用
- Li G, Zhang Z, Zhou L, et al. Chinese herbal formula Xuefu Zhuyu for primary dysmenorrhea patients (CheruPDYS): a study protocol for a randomized placebo-controlled trial. Trials. 2021. PMID: 33499921. doi:10.1186/s13063-021-05050-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。